Registered title, quoted from ClinicalTrials.gov
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07721103, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 1
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (1 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07721103, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
-
Participants must meet all of the following criteria:
Provide written informed consent before enrollment.
Age >18 years, male or female.
Histologically confirmed thoracic esophageal squamous cell carcinoma (ESCC).
Locally advanced, resectable disease according to AJCC/UICC 8th edition TNM staging system, defined as:
cT3-4aN0-2M0 or cT1-2N1-2M0;
No evidence of distant metastasis;
Considered initially resectable by a multidisciplinary surgical team.
Patients who have received neoadjuvant chemoimmunotherapy and have measurable disease response assessment according to RECIST v1.1, including complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).
At least one measurable lesion according to RECIST version 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival time >6 months.
Adequate organ function meeting the following criteria:
Bone marrow function:
Absolute neutrophil count ≥1,500/mm³;
Platelet count ≥100,000/mm³;
Hemoglobin ≥9 g/dL.
Renal function:
Serum creatinine ≤1.5 mg/dL and/or creatinine clearance ≥60 mL/min.
Hepatic function:
Total bilirubin ≤1.5 × upper limit of normal (ULN);
AST and ALT ≤1.5 × ULN.
Participants of childbearing potential must agree to use medically approved contraception during study treatment and for 3 months after completion of treatment. Female participants of childbearing potential must have a negative serum or urine pregnancy test within 7 days before enrollment and must not be breastfeeding.
Willingness and ability to comply with study procedures, safety assessments, and survival follow-up.
Exclusion Criteria:
-
Participants will be excluded if any of the following criteria apply:
Evidence of distant metastasis.
Previous or concurrent malignancy, except adequately treated basal cell carcinoma of skin or cervical carcinoma in situ.
Previous thoracic radiotherapy.
Previous treatment with PD-1, PD-L1, or CTLA-4 inhibitors, or known hypersensitivity to PD-1 inhibitors or macromolecular protein products.
Active autoimmune disease or history of clinically significant autoimmune disease requiring systemic treatment.
Current use of immunosuppressive therapy or systemic corticosteroids exceeding the equivalent of prednisone 10 mg/day within 2 weeks before enrollment.
Clinically significant ascites or pleural effusion requiring therapeutic drainage.
Uncontrolled cardiovascular disease, including:
NYHA class II or higher heart failure;
Unstable angina;
Myocardial infarction within 1 year;
Clinically significant arrhythmias requiring treatment.
Significant coagulation abnormalities, bleeding tendency, or ongoing thrombolytic/anticoagulant therapy.
Active gastrointestinal disorders associated with bleeding or perforation risk, including esophageal varices, active gastric/duodenal ulcer, ulcerative colitis, portal hypertension, or active tumor bleeding.
History of severe bleeding, clinically significant hemoptysis, or thromboembolic events within specified periods.
Active infection or unexplained fever >38.5°C before treatment initiation.
Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks before study treatment.
History or evidence of interstitial lung disease, pulmonary fibrosis, radiation pneumonitis, drug-induced pneumonitis, pneumoconiosis, or severe pulmonary impairment.
Known immunodeficiency, including HIV infection, or active hepatitis infection requiring exclusion according to protocol criteria.
Participation in another clinical trial within 1 month before enrollment or concurrent systemic anticancer therapy.
Receipt of live vaccines within 4 weeks before treatment or planned live vaccination during study treatment.
Known history of substance abuse, alcoholism, or drug abuse.
Inability or unwillingness to comply with study-related procedures, examinations, or required costs.
Any other medical, psychological, social, or safety-related condition judged by the investigator to make the participant unsuitable for study participation.
Quoted from ClinicalTrials.gov, NCT07721103, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07721103, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.